StreetAlpha.app
Home › Stocks › INO

Inovio Pharmaceuticals, Inc. (INO)

Healthcare
$1.63
▲ +16.43%
LAST CLOSE · NOV 17

INOVIO develops DNA medicines and CELLECTRA delivery devices for diseases linked to HPV, cancer and infectious diseases. It last closed at $1.63 on Nov 17, up 16.43% on the day. INO last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 3 analysts is $6.33 (+288.5% from the last close), with a high of $8.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in INO, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $239K, the largest $122K.

AI Auto Pilots
Is INO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$299K
+63.9% vs a year ago
Net income
−$71.1M
−23798.9% margin
EPS (diluted)
−$0.59
Free cash flow
−$74.4M
−24894.9% margin
Valuation
Market cap
$305.3M
187.3M shares
P/E
–
No P/E while losing money
Price to sales
1021.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$47.0M
At Sep 30
Shareholder equity
−$33.9M
Shares outstanding
187.3M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.8M$1.8MFY2021FY2022: $10.3M$10.3MFY2022FY2023: $832K$832KFY2023FY2024: $218K$218KFY2024FY2025: $65K$65KFY2025

From INO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · After the close (AMC)
Reported EPS
-$0.23
vs -$0.20 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±11.4%
Priced in before that report
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on INO in the past 90 days
Average 12-month target
$6.33
▲ 288.5% upside

Based on 3 analysts who set a price target on INO in the past 90 days. The average target is $6.33, with a high of $8.00 and a low of $5.00, compared with the last close of $1.63.

$0$3$6$9PAST 12 TRADING DAYS12-MONTH TARGETSHIGH $8AVG $6.33LOW $5May 22LAST CLOSE+12 MO$0$3$6$9PAST 12 DAYSTARGETSHIGH $8AVG $6.33LOW $5May 22LAST CLOSE+12 MO
Highest target$8.00
Average target$6.33
Lowest target$5.00
Latest rating changes
Piper SandlerTarget raised
Nov 11Buy$4 → $6
JefferiesTarget raised
Nov 7Buy$3 → $8
HC Wainwright & Co.Upgrade
Nov 2Buy$2.50 → $5
JefferiesUpgrade
Aug 13Buy$3
Piper SandlerReiterated
Aug 3Buy$4
DateFirmActionRatingPrice target
Nov 11Piper SandlerTarget raisedBuy$4 → $6
Nov 7JefferiesTarget raisedBuy$3 → $8
Nov 2HC Wainwright & Co.UpgradeBuy$2.50 → $5
Aug 13JefferiesUpgradeBuy$3
Aug 3Piper SandlerReiteratedBuy$4
Loading…

Technical Analysis

INO · as of the Nov 17 close · updated after every close
Uptrend

The stock is 24% above its 20 day and 27% above its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot at $1.55, and the nearest resistance the Pivot R1 at $1.72.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 14.0%/day
Key levels
$2.7252 week high+66.9%
$2.17Swing high (Nov 2)+33.1%
$1.72Pivot R1+5.5%
$1.63Last close
$1.55Pivot−4.9%
$1.46Pivot S1−10.4%
$1.26200 day average−22.7%
$1.2420 day average−23.9%
$1.22Swing low (Sep 1)−25.2%
$1.1950 day average−27.0%
$1.14100 day average−30.1%
$0.5652 week low−65.6%
Indicators
RSI (14)60.12Strong, overbought above 70Neutral
MACD0.12Above its signal lineBullish
Stochastic56.6Middle of its rangeNeutral
ADX (14)24.3Weak trend
Williams %R-34.3Oversold below −80, overbought above −20Neutral
CCI (20)61.5Oversold below −100, overbought above 100Neutral
Rate of change−1.8%Change over 10 sessionsBearish
ATR (14)$0.23Typical daily range, 14.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for INO

What happened before

See how INO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow INO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How INO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Nov 6 – Nov 6
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$239K
Largest print
$122K
Loading…

INO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲58 buying vs 34 selling
  • ▲Held by funds +16.0 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding111107+3.7%
In funds' top 1000–
Held by funds33.6%17.6%+16.0 pts
New / increased23 / 3522 / 27+18.4%
Reduced / sold out15 / 1914 / 18+6.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INO is in one of them and how their past INO trades turned out.

INO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INO in an article yet. Here's the latest on the wider market.

INO Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 6
Who traded INO · since 2020
Latest 1 filing
$1K – $15KTraded Sep 8, 2020Filed Nov 6, 2020
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KSep 8, 2020Nov 6, 202059 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Inovio Pharmaceuticals

INOVIO is a biotechnology company based in Plymouth Meeting, Pennsylvania. It develops DNA medicines meant to help treat and prevent diseases linked to human papillomavirus (HPV), certain cancers and infectious diseases. Its lead candidate, INO-3107, is being studied for recurrent respiratory papillomatosis, a rare condition that causes tumors in the airway. The company also develops CELLECTRA devices that deliver these medicines into the body's cells. Its intended customers are patients and the healthcare providers who treat them.

Headquarters
Plymouth Meeting, PA
Founded
1983